Pataday Once Daily Relief Extra Strength Available Over-the-Counter
Pataday Once Daily Relief Extra Strength is indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander.
Pataday Once Daily Relief Extra Strength is indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander.
Refresh Digital is designed to protect tears from evaporating due to incomplete blinking during digital device use.
The NDA submission is supported by data from the phase 3 MIST-1 and MIST-2 studies.
Previously, the device had only been approved in those with episodic migraine.
The application is supported by data from the double-blind, placebo-controlled phase 3 VOYAGER PAD trial.
EyeArt is the first FDA-cleared AI technology for autonomous detection of more than mild diabetic retinopathy and vision-threatening diabetic retinopathy.
The FDA has granted Fast Track designation to Zimura (avacincaptad pegol; Iveric Bio) for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
Cystinosis is a rare, multisystem genetic disorder caused by an accumulation of cystine crystals throughout the body, including the eyes.
The Food and Drug Administration (FDA) has approved Tepezza™ (teprotumumab-trbw; Horizon Therapeutics) for the treatment of thyroid eye disease.